Research & Literature
Explore the leading researchers and institutions driving advances in this area, and dive into the full body of literature that informs this resource.
Top Authors
Top Institutions
Finding nearby institutions...
The University of Texas MD Anderson Cancer Center
Houston, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Moffitt Cancer Center
Tampa, United States
Harvard University
Cambridge, United States
University of Zurich
Zurich, Switzerland
Northwestern University
Evanston, United States
Yale University
New Haven, United States
University of Turin
Turin, Italy
The Netherlands Cancer Institute
Amsterdam, The Netherlands
Medical University of Vienna
Vienna, Austria
References
References (68)
- 1
Therapy of leptomeningeal metastasis in solid tumors.
Mack F, Baumert BG, Schäfer N, et al.
Cancer treatment reviews 2016; (43()):83-91.
PMID: 26827696 - 2
Leptomeningeal carcinomatosis as primary manifestation of pancreatic cancer.
Trinh VT, Medina-Flores R, Chohan MO
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016; (30()):124-127 doi:10.1016/j.jocn.2015.12.027.
PMID: 26972704 - 3
Leptomeningeal metastases: a RANO proposal for response criteria.
Chamberlain M, Junck L, Brandsma D, et al.
Neuro-oncology 2017; (19(4)):484-492 doi:10.1093/neuonc/now183.
PMID: 28039364 - 4
Surgical Treatment for Leptomeningeal Disease.
Volkov AA, Filis AK, Vrionis FD
Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):47-53 doi:10.1177/107327481702400107.
PMID: 28178712 - 5
Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.
Boire A, Zou Y, Shieh J, et al.
Cell 2017; (168(6)):1101-1113.e13 doi:10.1016/j.cell.2017.02.025.
PMID: 28283064 - 6
Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors.
Chowdhary S, Damlo S, Chamberlain MC
Cancer control : journal of the Moffitt Cancer Center 2017; (24(1)):S1-S16 doi:10.1177/107327481702400118.
PMID: 28557973 - 7
Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.
Lin X, Fleisher M, Rosenblum M, et al.
Neuro-oncology 2017; (19(9)):1248-1254 doi:10.1093/neuonc/nox066.
PMID: 28821205 - 8
Leptomeningeal metastasis.
Taillibert S, Chamberlain MC
Handbook of clinical neurology 2018; (149()):169-204 doi:10.1016/B978-0-12-811161-1.00013-X.
PMID: 29307353 - 9
Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.
Ballester LY, Glitza Oliva IC, Douse DY, et al.
Journal of neuropathology and experimental neurology 2018; (77(7)):628-635 doi:10.1093/jnen/nly046.
PMID: 29873738 - 10
The Comparative Treatment of Intraventricular Chemotherapy by Ommaya Reservoir vs. Lumbar Puncture in Patients With Leptomeningeal Carcinomatosis.
Montes de Oca Delgado M, Cacho Díaz B, Santos Zambrano J, et al.
Frontiers in oncology 2018; (8()):509 doi:10.3389/fonc.2018.00509.
PMID: 30524956 - 11
Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study.
Mitsuya K, Nakasu Y, Hayashi N, et al.
PloS one 2019; (14(1)):e0210074 doi:10.1371/journal.pone.0210074.
PMID: 30629621 - 12
Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).
Ferguson SD, Bindal S, Bassett RL, et al.
Journal of neuro-oncology 2019; (142(3)):499-509 doi:10.1007/s11060-019-03121-2.
PMID: 30847840 - 13
Clinical outcome of cerebrospinal fluid shunts in patients with leptomeningeal carcinomatosis.
Kim HS, Park JB, Gwak HS, et al.
World journal of surgical oncology 2019; (17(1)):59 doi:10.1186/s12957-019-1595-7.
PMID: 30917830 - 14
How we treat patients with leptomeningeal metastases.
Le Rhun E, Preusser M, van den Bent M, et al.
ESMO open 2019; (4(Suppl 2)):e000507 doi:10.1136/esmoopen-2019-000507.
PMID: 31231573 - 15
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.
Glitza IC, Smalley KSM, Brastianos PK, et al.
Pigment cell & melanoma research 2020; (33(4)):527-541 doi:10.1111/pcmr.12861.
PMID: 31916400 - 16
Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R, Vordermark D, Hassel JC, et al.
Cancer treatment reviews 2020; (89()):102083 doi:10.1016/j.ctrv.2020.102083.
PMID: 32736188 - 17
An overview of leptomeningeal disease.
Nguyen TK, Nguyen EK, Soliman H
Annals of palliative medicine 2021; (10(1)):909-922 doi:10.21037/apm-20-973.
PMID: 32921068 - 18
Impact of New Systemic Treatment and Radiotherapy in Melanoma Patients with Leptomeningeal Metastases.
Tétu P, Sirven-Villaros L, Cuzzubbo S, et al.
Cancers 2020; (12(9)) doi:10.3390/cancers12092635.
PMID: 32947841 - 19
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
Le Rhun E, Devos P, Weller J, et al.
Neuro-oncology 2021; (23(7)):1100-1112 doi:10.1093/neuonc/noaa298.
PMID: 33367859 - 20
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E, Kebir S, Ahmed MS, et al.
European journal of cancer (Oxford, England : 1990) 2021; (148()):395-404 doi:10.1016/j.ejca.2021.02.016.
PMID: 33789203 - 21
Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid.
White MD, Klein RH, Shaw B, et al.
JAMA network open 2021; (4(8)):e2120040 doi:10.1001/jamanetworkopen.2021.20040.
PMID: 34369989 - 22
Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.
Bander ED, Yuan M, Reiner AS, et al.
Journal of neuro-oncology 2021; (154(3)):301-313 doi:10.1007/s11060-021-03827-2.
PMID: 34406564 - 23
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
Brastianos PK, Strickland MR, Lee EQ, et al.
Nature communications 2021; (12(1)):5954 doi:10.1038/s41467-021-25859-y.
PMID: 34642329 - 24
CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.
Najem H, Marisetty A, Horbinski C, et al.
Frontiers in immunology 2021; (12()):745893 doi:10.3389/fimmu.2021.745893.
PMID: 34691054 - 25
Leptomeningeal Carcinomatosis: A Call for Optimizing Diagnostic Sensitivity by the Hematology Laboratory.
Lardinois B, Miller L, Randazzo A, et al.
Case reports in oncology 2021; (14(2)):1248-1253 doi:10.1159/000518314.
PMID: 34703443 - 26
Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.
Piña Y, Yadugiri S, Yeboa DN, et al.
Current oncology reports 2022; (24(1)):43-54 doi:10.1007/s11912-021-01162-3.
PMID: 35059999 - 27
Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases.
Lowe SR, Wang CP, Brisco A, et al.
Neuro-oncology 2022; (24(8)):1307-1317 doi:10.1093/neuonc/noac023.
PMID: 35092434 - 28
Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.
Ozcan G, Singh M, Vredenburgh JJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(1)):11-29 doi:10.1158/1078-0432.CCR-22-1585.
PMID: 35972437 - 29
Case Report: Focal leptomeningeal disease, atypical cancer of unknown primary site.
Vences MA, Araujo-Chumacero MM, Urrunaga-Pastor D, et al.
F1000Research 2022; (11()):885 doi:10.12688/f1000research.122434.2.
PMID: 36188732 - 30
Diagnostic accuracy of cerebrospinal fluid liquid biopsy and MRI for leptomeningeal metastases in solid cancers: A systematic review and meta-analysis.
Nakasu Y, Deguchi S, Nakasu S, et al.
Neuro-oncology advances 2023; (5(1)):vdad002 doi:10.1093/noajnl/vdad002.
PMID: 36968290 - 31
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.
Khaled ML, Tarhini AA, Forsyth PA, et al.
Cancers 2023; (15(6)) doi:10.3390/cancers15061884.
PMID: 36980770 - 32
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Glitza Oliva IC, Ferguson SD, Bassett R, et al.
Nature medicine 2023; (29(4)):898-905 doi:10.1038/s41591-022-02170-x.
PMID: 36997799 - 33
[Spinal metastases combined with leptomeningeal metastasis: A case report].
Ma LJ, Hu PP, Liu XG
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2023; (55(3)):563-566.
PMID: 37291936 - 34
Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J, Gellrich FF, Engellandt K, et al.
International journal of molecular sciences 2023; (24(14)) doi:10.3390/ijms241411443.
PMID: 37511202 - 35
Survival and quality of life after CSF diversion in adult patients with leptomeningeal metastasis-associated hydrocephalus: a systematic review and meta-analysis.
Dhaliwal J, Ruiz-Perez M, Mihaela-Vasilica A, et al.
Neurosurgical focus 2023; (55(2)):E16 doi:10.3171/2023.5.FOCUS23195.
PMID: 37527677 - 36
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.
Smalley I, Boire A, Brastianos P, et al.
Pigment cell & melanoma research 2024; (37(1)):51-67 doi:10.1111/pcmr.13116.
PMID: 37622466 - 37
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.
Sherman WJ, Romiti E, Michaelides L, et al.
Current treatment options in oncology 2023; (24(12)):1962-1977 doi:10.1007/s11864-023-01155-3.
PMID: 38158477 - 38
Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease.
Alhaddad H, Ospina OE, Khaled ML, et al.
bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.12.18.572266.
PMID: 38187574 - 39
Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSideTM.
Puri S, Malani R, Chalmers A, et al.
Neuro-oncology advances 2024; (6(1)):vdad150 doi:10.1093/noajnl/vdad150.
PMID: 38196737 - 40
Ventriculoperitoneal shunting with an on-off valve for patients with leptomeningeal metastases and intracranial hypertension.
Huntoon KM, Gasco J, Glitza Oliva IC, et al.
Neuro-oncology practice 2024; (11(1)):56-63 doi:10.1093/nop/npad056.
PMID: 38222058 - 41
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
Sener U, Webb M, Breen WG, et al.
Journal of immunotherapy and precision oncology 2024; (7(1)):1-6 doi:10.36401/JIPO-23-20.
PMID: 38327758 - 42
Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.
Barbour AB, Kotecha R, Lazarev S, et al.
Advances in radiation oncology 2024; (9(2)):101377 doi:10.1016/j.adro.2023.101377.
PMID: 38405313 - 43
Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors.
Barbour AB, Blouw B, Taylor LP, et al.
Journal of neuro-oncology 2024; (167(3)):509-514 doi:10.1007/s11060-024-04615-4.
PMID: 38441840 - 44
The anatomic basis of leptomeningeal metastasis.
Freret ME, Boire A
The Journal of experimental medicine 2024; (221(4)) doi:10.1084/jem.20212121.
PMID: 38451255 - 45
Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease.
Law V, Smalley I, Evernden BR, et al.
Journal of visualized experiments : JoVE 2024; doi:10.3791/66071.
PMID: 38619274 - 46
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.
Wilcox JA, Chukwueke UN, Ahn MJ, et al.
Neuro-oncology 2024; (26(10)):1781-1804 doi:10.1093/neuonc/noae103.
PMID: 38902944 - 47
Detection of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series.
Dirven I, Vounckx M, Kessels JI, et al.
Pigment cell & melanoma research 2024; (37(6)):822-830 doi:10.1111/pcmr.13186.
PMID: 38990845 - 48
Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.
Saberian C, Milton DR, Simon J, et al.
Neuro-oncology practice 2024; (11(4)):452-463 doi:10.1093/nop/npae026.
PMID: 39006528 - 49
NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases.
Le Rhun E, Nayak L, Lim-Fat MJ, et al.
Neuro-oncology 2025; (27(2)):455-465 doi:10.1093/neuonc/noae171.
PMID: 39208403 - 50
A Rare Cause of Cauda Equina Syndrome: Neuroendocrine Carcinoma of the Lung.
Ford PH, Carbo E, Rennie A, Virgilio R
Cureus 2024; (16(9)):e69263 doi:10.7759/cureus.69263.
PMID: 39282491 - 51
Leptomeningeal Disease Secondary to Invasive Ductal Carcinoma of the Breast: A Rapidly Progressive and Fatal Complication.
Dhawan S, Mattathil F, Malik I, et al.
Cureus 2024; (16(11)):e74421 doi:10.7759/cureus.74421.
PMID: 39600551 - 52
Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).
Pedersen S, Johansen EL, Højholt KL, et al.
European journal of cancer (Oxford, England : 1990) 2025; (217()):115253 doi:10.1016/j.ejca.2025.115253.
PMID: 39874911 - 53
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
Long GV, Atkinson V, Lo SN, et al.
The Lancet. Oncology 2025; (26(3)):320-330 doi:10.1016/S1470-2045(24)00735-6.
PMID: 39978375 - 54
Lumboperitoneal and ventriculoperitoneal shunting for leptomeningeal disease-associated hydrocephalus: a systematic review and meta-analysis of postoperative outcomes and comparative effectiveness.
Hajikarimloo B, Mohammadzadeh I, Tos SM, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(10)):4899-4912 doi:10.1007/s10072-025-08321-5.
PMID: 40550976 - 55
Long-term survival in a patient with brain metastases and leptomeningeal disease of breast cancer: a case report of a patient receiving trastuzumab-deruxtecan.
von Kroge P, Müller V, Schmalfeldt B, et al.
Archives of gynecology and obstetrics 2025; (312(5)):1821-1827 doi:10.1007/s00404-025-08096-2.
PMID: 40627061 - 56
Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics.
Faillot M, Goldwirt L, Jouenne F, et al.
Neurosurgery 2026; (99(4)):882-889 doi:10.1227/neu.0000000000003924.
PMID: 41636506 - 57
Pathophysiology and treatment of leptomeningeal metastases in lung cancer.
Hida T
Translational lung cancer research 2026; (15(1)):19 doi:10.21037/tlcr-2025-aw-1247.
PMID: 41659263 - 58
Cerebrospinal Fluid Shunting in Hydrocephalus Secondary to Leptomeningeal Metastases: A Systematic Review and Meta-Analysis of Functional Outcomes, Symptom Improvement, and Complications.
Alomari O, Uslu I, Kılıç D, et al.
World neurosurgery 2026; (209()):124901 doi:10.1016/j.wneu.2026.124901.
PMID: 41796675 - 59
Melanoma leptomeningeal disease: Advances in diagnosis and emerging therapeutic strategies.
Middleton ML, Lucke-Wold B
World journal of experimental medicine 2026; (16(1)):117938 doi:10.5493/wjem.v16.i1.117938.
PMID: 41883443 - 60
Utility of cerebrospinal fluid circulating tumor cell quantification and next-generation sequencing in patients with suspicion for leptomeningeal disease.
Onoichenco A, Galvez R, Schultz A, et al.
Neuro-oncology advances 2026; (8(1)):vdag046 doi:10.1093/noajnl/vdag046.
PMID: 41924095 - 61
Outcomes and prognostic factors in melanoma patients with leptomeningeal disease: a retrospective cohort study.
Aboelatta MA, Rezazadeh A, Sener U, et al.
Melanoma research 2026; (36(3)):203-210 doi:10.1097/CMR.0000000000001088.
PMID: 42053986 - 62
Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.
Weindler S, Hundsberger T, Addeo A, et al.
Oncology 2026; (104(10)):1203-1214 doi:10.1159/000552332.
PMID: 42166400 - 63
Lumbar-ventricular cerebrospinal fluid pressure discrepancy in leptomeningeal metastasis associated intracranial hypertension.
Chang KW, Jeon WJ, Lee WJ, et al.
Fluids and barriers of the CNS 2026; (23(1)).
PMID: 42218510 - 64
H3K27M-Mutant Diffuse Leptomeningeal Glioneuronal Tumor Presenting as Communicating Hydrocephalus: Case Report and Literature Review.
Narendrakumar A, Mishra S, Kumar A, et al.
Pediatric neurosurgery 2026; 1 doi:10.1159/pne/aeiag003.
PMID: 42599848 - 65
Survival and hematologic toxicity after whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation for solid-tumor leptomeningeal disease: a systematic review.
Munir M, Sehrawat K, Hassan H, et al.
Journal of neuro-oncology 2026; (179(2)).
PMID: 42667527 - 66
Spinal leptomeningeal disease in patients with solid tumors: A single-center study on clinical presentation, diagnosis, treatment, and outcomes.
Shaked Z, Eitner C, Jelgersma C, et al.
Brain & spine 2026; (6()):106660 doi:10.1016/j.bas.2026.106660.
PMID: 42825100 - 67
Multi-omics liquid biopsy for leptomeningeal metastases in lung cancer: from molecular mechanisms to precision diagnosis and treatment.
Zhang R, Zhao Q, Cao Y, et al.
Lung cancer (Amsterdam, Netherlands) 2026; (222()):109667 doi:10.1016/j.lungcan.2026.109667.
PMID: 42893629 - 68
Carcinomatous meningitis: Current insights into diagnosis, prognosis and management.
Gambaretti M, Lavalley A, Ollivier M, et al.
La Revue de medecine interne 2026; doi:10.1016/j.revmed.2026.09.016.
PMID: 42907241